Home / ATYR : NASDAQ

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does ATYR make money? Does ATYR have pricing power? What's the Earnings Whisper? Will ATYR profit more as the business scales? What is ATYR's management track record? Is ATYR's current price justified?

aTyr Pharma, Inc.

$0.38 -$0.38 (-49.69%)

NASDAQ · 15 Sep 2026 14:53 UTC

Previous Close

$0.39

Day Range

$0.38$0.4

Year Range

$0.38$1.2

Market Cap

37.45M

AVG Volume

2.11M

Trailing/Forward PE

-0.62/-

PEG ratio

0.25

Dividend Yield

Next Earnings Date

2026-11-05

Primary Exchange

NASDAQ

Revenue (USD) · TTM

ATYR Revenue (USD) · TTM by quarter
Period	Revenue (USD) · TTM
26 Q2	190K
26 Q1	190K
25 Q4	190K
25 Q3	190K
25 Q2	0
25 Q1	0
24 Q4	235K
24 Q3	235K
24 Q2	588K
24 Q1	588K

Net Income (USD) · TTM

ATYR Net Income (USD) · TTM by quarter
Period	Net Income (USD) · TTM
26 Q2	-60.81M
26 Q1	-70.03M
25 Q4	-74.12M
25 Q3	-75.12M
25 Q2	-66.64M
25 Q1	-63.41M
24 Q4	-64.02M
24 Q3	-63.82M
24 Q2	-57.9M
24 Q1	-53.93M

Operating Income (USD) · TTM

ATYR Operating Income (USD) · TTM by quarter
Period	Operating Income (USD) · TTM
26 Q2	-63.86M
26 Q1	-73.29M
25 Q4	-77.63M
25 Q3	-78.65M
25 Q2	-70.05M
25 Q1	-67.05M
24 Q4	-67.91M
24 Q3	-68.05M
24 Q2	-62.52M
24 Q1	-58.77M

EBITDA (USD) · TTM

ATYR EBITDA (USD) · TTM by quarter
Period	EBITDA (USD) · TTM
26 Q2	-58.54M
26 Q1	-68.69M
25 Q4	-72.79M
25 Q3	-74.02M
25 Q2	-65.31M
25 Q1	-62.09M
24 Q4	-62.31M
24 Q3	-61.87M
24 Q2	-55.34M
24 Q1	-51.18M

Cash Flows (USD) · TTM

ATYR Cash Flows (USD) · TTM by quarter
Period	Cash Flows (USD) · TTM
26 Q2	-54.82M
26 Q1	-59.3M
25 Q4	-62.06M
25 Q3	-62.99M
25 Q2	-55.65M
25 Q1	-62.21M
24 Q4	-69.18M
24 Q3	-67.11M
24 Q2	-64.05M
24 Q1	-58M

EPS (USD) · TTM

ATYR EPS (USD) · TTM by quarter
Period	EPS (USD) · TTM
26 Q2	-0.62
26 Q1	-0.73
25 Q4	-0.79
25 Q3	-0.83
25 Q2	-0.8
25 Q1	-0.81
24 Q4	-0.87
24 Q3	-0.94
24 Q2	-0.91
24 Q1	-0.9

Expenses (USD) · TTM

ATYR Expenses (USD) · TTM by quarter
Period	Expenses (USD) · TTM
26 Q2	64.33M
26 Q1	73.69M
25 Q4	77.89M
25 Q3	78.91M
25 Q2	70.1M
25 Q1	67.1M
24 Q4	68.21M
24 Q3	67.94M
24 Q2	62.31M
24 Q1	60.36M

Shares Outstanding · TTM

ATYR Shares Outstanding · TTM by quarter
Period	Shares Outstanding · TTM
26 Q2	-4.97M
26 Q1	-5.13M
25 Q4	-5M
25 Q3	-4.56M
25 Q2	-4M
25 Q1	-3.43M
24 Q4	-2.99M
24 Q3	-2.88M
24 Q2	-2.79M
24 Q1	-2.72M

Employee Count

ATYR Employee Count by quarter
Period	Employee Count
2025	56
2024	56
2023	56
2022	65
2021	49
2020	40
2019	39
2018	42
2017	65
2016	58

Free Cash Flow Yield

ATYR Free Cash Flow Yield by quarter
Period	Free Cash Flow Yield
Sep 26	-143.84%
Sep 26	-130.06%
Sep 26	-112.4%
Aug 26	-103.51%
Aug 26	-111.46%
Aug 26	-100%
Aug 26	-109.3%
Jul 26	-124.52%
Jul 26	-127.79%
Jul 26	-118.64%
Jul 26	-111.1%
Jul 26	-102.08%
Jun 26	-114.66%
Jun 26	-134.25%
Jun 26	-137.33%
Jun 26	-128.68%
May 26	-111.49%
May 26	-123.43%
May 26	-120%
May 26	-66.92%
May 26	-75.97%
Apr 26	-80.66%
Apr 26	-74.2%
Apr 26	-76.07%
Apr 26	-74.77%
Mar 26	-84.21%
Mar 26	-78.34%
Mar 26	-74.5%
Mar 26	-76.85%
Feb 26	-67.55%
Feb 26	-62.34%
Feb 26	-72.53%
Feb 26	-72.12%
Jan 26	-73.45%
Jan 26	-89.67%
Jan 26	-91.5%
Jan 26	-90.98%
Jan 26	-85.42%
Dec 25	-87.29%
Dec 25	-86.45%
Dec 25	-83.61%
Dec 25	-78.7%
Nov 25	-83.07%
Nov 25	-97.58%
Nov 25	-86.08%
Nov 25	-79.37%
Oct 25	-71.31%
Oct 25	-63.95%
Oct 25	-60.54%
Oct 25	-58.26%
Oct 25	-79.66%
Sep 25	-73.47%
Sep 25	-62.25%
Sep 25	-10.24%
Sep 25	-11.01%
Aug 25	-11.48%
Aug 25	-11.54%
Aug 25	-12.6%
Aug 25	-11.65%
Aug 25	-15.3%
Jul 25	-12.34%
Jul 25	-12.01%
Jul 25	-13.57%
Jul 25	-13.55%
Jun 25	-14.3%
Jun 25	-13.78%
Jun 25	-13.83%
Jun 25	-13.37%
May 25	-16.09%
May 25	-19.18%
May 25	-22%
May 25	-21.93%
May 25	-23.23%
Apr 25	-24.96%
Apr 25	-26.98%
Apr 25	-28.16%
Apr 25	-31.92%
Mar 25	-26.72%
Mar 25	-22.73%
Mar 25	-21.07%
Mar 25	-26.04%
Feb 25	-22.36%
Feb 25	-20.49%
Feb 25	-25.96%
Feb 25	-22.7%
Jan 25	-22.93%
Jan 25	-24.66%
Jan 25	-24.52%
Jan 25	-25.08%
Jan 25	-22.24%
Dec 24	-23.67%
Dec 24	-26.43%
Dec 24	-28.93%
Dec 24	-26.35%
Nov 24	-25.08%
Nov 24	-29.22%
Nov 24	-30.42%
Nov 24	-28.37%
Nov 24	-29.15%
Oct 24	-27.26%

Price to Sales

ATYR Price to Sales by quarter
Period	Price to Sales
Sep 26	200.58
Sep 26	221.84
Sep 26	256.69
Aug 26	278.73
Aug 26	258.85
Aug 26	288.53
Aug 26	263.96
Jul 26	250.63
Jul 26	244.23
Jul 26	263.07
Jul 26	280.92
Jul 26	305.74
Jun 26	272.2
Jun 26	232.47
Jun 26	227.26
Jun 26	242.53
May 26	279.94
May 26	252.85
May 26	260.07
May 26	488.14
May 26	429.95
Apr 26	404.99
Apr 26	440.22
Apr 26	429.39
Apr 26	436.87
Mar 26	387.91
Mar 26	416.96
Mar 26	438.47
Mar 26	425.05
Feb 26	490.78
Feb 26	531.79
Feb 26	457.08
Feb 26	459.69
Jan 26	451.41
Jan 26	369.75
Jan 26	362.33
Jan 26	364.43
Jan 26	388.15
Dec 25	379.82
Dec 25	383.5
Dec 25	396.54
Dec 25	421.29
Nov 25	399.1
Nov 25	339.78
Nov 25	385.14
Nov 25	417.71
May 25	1267.27
Apr 25	1179.27
Apr 25	1091.26
Apr 25	1045.5
Apr 25	922.29
Mar 25	1101.82
Mar 25	1295.43
Mar 25	1397.52
Mar 25	1096.7
Feb 25	1277.34
Feb 25	1393.46
Feb 25	1099.93
Feb 25	1257.99
Jan 25	1245.08
Jan 25	1157.99
Jan 25	1164.44
Jan 25	1138.64
Jan 25	1283.79
Dec 24	1206.38
Dec 24	1080.58
Dec 24	987.03
Dec 24	1083.8
Nov 24	1138.64
Nov 24	977.36
Nov 24	938.65
Nov 24	1006.39
Nov 24	373.72
Oct 24	399.53
Oct 24	367.57
Oct 24	274.14
Oct 24	229.88
Sep 24	217.59
Sep 24	223.74
Sep 24	233.57
Sep 24	231.11
Aug 24	229.88
Aug 24	232.34
Aug 24	234.8
Aug 24	204.54
Aug 24	205.66
Jul 24	249.49
Jul 24	184.31
Jul 24	195.54
Jul 24	169.7
Jun 24	175.32
Jun 24	167.45
Jun 24	205.66
Jun 24	222.52
May 24	194.42

Price to Book

ATYR Price to Book by quarter
Period	Price to Book
Sep 26	0.78
Sep 26	0.87
Sep 26	1
Aug 26	1.09
Aug 26	1.01
Aug 26	1.13
Aug 26	1.03
Jul 26	0.82
Jul 26	0.8
Jul 26	0.87
Jul 26	0.92
Jul 26	1.01
Jun 26	0.9
Jun 26	0.76
Jun 26	0.75
Jun 26	0.8
May 26	0.92
May 26	0.83
May 26	0.86
May 26	1.38
May 26	1.21
Apr 26	1.14
Apr 26	1.24
Apr 26	1.21
Apr 26	1.23
Mar 26	1.1
Mar 26	1.18
Mar 26	1.24
Mar 26	1.2
Feb 26	1.16
Feb 26	1.26
Feb 26	1.08
Feb 26	1.09
Jan 26	1.07
Jan 26	0.88
Jan 26	0.86
Jan 26	0.87
Jan 26	0.92
Dec 25	0.9
Dec 25	0.91
Dec 25	0.94
Dec 25	1
Nov 25	0.95
Nov 25	0.81
Nov 25	0.91
Nov 25	0.99
Oct 25	1.05
Oct 25	1.17
Oct 25	1.23
Oct 25	1.28
Oct 25	0.94
Sep 25	1.01
Sep 25	1.2
Sep 25	7.28
Sep 25	6.77
Aug 25	6.49
Aug 25	6.46
Aug 25	5.91
Aug 25	6.4
Aug 25	5.43
Jul 25	6.74
Jul 25	6.92
Jul 25	6.12
Jul 25	6.13
Jun 25	5.81
Jun 25	6.03
Jun 25	6.01
Jun 25	6.22
May 25	5.16
May 25	4.33
May 25	3.78
May 25	3.79
May 25	4.26
Apr 25	3.97
Apr 25	3.67
Apr 25	3.52
Apr 25	3.1
Mar 25	3.71
Mar 25	4.36
Mar 25	4.7
Mar 25	3.96
Feb 25	4.61
Feb 25	5.03
Feb 25	3.97
Feb 25	4.54
Jan 25	4.49
Jan 25	4.18
Jan 25	4.2
Jan 25	4.11
Jan 25	4.63
Dec 24	4.35
Dec 24	3.9
Dec 24	3.56
Dec 24	3.91
Nov 24	4.11
Nov 24	3.53
Nov 24	3.39
Nov 24	3.63
Nov 24	2.7
Oct 24	2.89

No video analysis for this stock yet. Request one from our team.

News: ATYR

globenewswire.com · 1 Sep 2026

aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis

SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today provided an update on the expected timing of a response from the U.S. Food and Drug Administration (FDA) related to the protocol the Company submitted in June 2026 for a planned Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease.

globenewswire.com · 7 Aug 2026

aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD

Company awaiting comments from FDA by the end of August 2026 on protocol submitted for planned Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis. Workforce reduction of approximately 60% and program prioritization conserves capital and aligns resources on efzofitimod program in ILD.

globenewswire.com · 15 Jul 2026

aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026

Patients with restrictive lung disease demonstrate clinically meaningful benefit in FVC and improvements in multiple PROs for 5.0 mg/kg efzofitimod compared to placebo. Company submitted protocol to FDA in June 2026 for planned Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease.